Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

You’ve supercharged your research process with ACS and Mendeley!

Click to create an ACS ID

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Your Mendeley pairing has expired. Please reconnect
ACS Publications. Most Trusted. Most Cited. Most Read
My Activity

Figure 1Loading Img

Quantitative Proteomic Analysis of PCSK9 Gain of Function in Human Hepatic HuH7 Cells

View Author Information
Ottawa Institute of Systems Biology, University of Ottawa, Ontario, Canada
Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, University of Montreal, Montreal, Quebec, Canada
§ Chronic Disease Program, Ottawa Hospital Research Institute, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada
*Drs. Daniel Figeys and Janice Mayne, Ottawa Institute of Systems Biology, University of Ottawa. DF e-mail: [email protected]. Tel: 613-562-5800 ext 8674. Fax 613-562-5655. JM e-mail: [email protected]. Tel: 613-562-5800 ext 8073. Fax 613-562-5655.
Cite this: J. Proteome Res. 2011, 10, 4, 2011–2026
Publication Date (Web):February 18, 2011
Copyright © 2011 American Chemical Society

    Article Views





    Other access options
    Supporting Info (1)»


    Abstract Image

    Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in cholesterol homeostasis, mediating degradation of the liver low-density lipoprotein receptor (LDLR). In fact, gain- and loss-of-function PCSK9 variations in human populations associate with hyper- or hypo- cholesterolemia, respectively. Exactly how PCSK9 promotes degradation of the LDLR, the identity of the other biomolecules involved in this process, and the global effect of PCSK9 on other proteins has not been thoroughly studied. Here we employ stable isotope labeling with amino acids in cell culture (SILAC) to present the first quantitative, subcellular proteomic study of proteins affected by the stable overexpression of a gain-of-function PCSK9 membrane-bound chimera (PCSK9-V5-ACE2) in comparison to control, empty vector transfections in a human hepatocyte (HuH7) cell line. The expression level of 327 of 5790 peptides was modified by PCSK9-V5-ACE2 overexpression. Immunoblotting was carried out for the control transferrin receptor, shown to be unaffected in cells overexpressing PCSK9-V5-ACE2, thus validating our SILAC results. We also used immunoblotting to confirm the novel SILAC results of up- and down-regulation of several proteins in cells overexpressing PCSK9-V5-ACE2. Moreover, we documented the novel down-regulation of the EH domain binding protein-1 (EHBP1) in a transgenic PCSK9 mouse model and its up-regulation in a PCSK9 knockout mouse model.

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.


    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.

    Supporting Information

    Jump To

    Supplementary Table 1: Total list of quantified proteins. This material is available free of charge via the Internet at

    Terms & Conditions

    Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:

    Cited By

    This article is cited by 13 publications.

    1. Erica Gianazza, Chiara Macchi, Cristina Banfi, Massimiliano Ruscica. Proteomics and Lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: a narrative review. Frontiers in Cardiovascular Medicine 2023, 10
    2. Lei Huang, Ying Cheng, Yulian Mu, Kui Li, . PCSK9-D374Y Suppresses Hepatocyte Migration through Downregulating Free Cholesterol Efflux Rate and Activity of Extracellular Signal-Regulated Kinase. Analytical Cellular Pathology 2023, 2023 , 1-11.
    3. Chun-Xiao Liu, Rui-Xing Yin, Xiao-Li Cao, Zong-Hu Shi, Feng Huang, Bi-Liu Wei, Guo-Xiong Deng, Peng-Fei Zheng, Yao-Zong Guan. EHBP1, TUBB, and WWOX SNPs, Gene-Gene and Gene-Environment Interactions on Coronary Artery Disease and Ischemic Stroke. Frontiers in Genetics 2022, 13
    4. Takehiro Ando, Mizuki Yamamoto, Takumi Yokoyama, Daisuke Horiuchi, Takashi Kawakami. In vitro selection generates RNA aptamer that antagonizes PCSK9–LDLR interaction and recovers cellular LDL uptake. Journal of Bioscience and Bioengineering 2021, 131 (3) , 326-332.
    5. Brian T Emmer, Geoffrey G Hesketh, Emilee Kotnik, Vi T Tang, Paul J Lascuna, Jie Xiang, Anne-Claude Gingras, Xiao-Wei Chen, David Ginsburg. The cargo receptor SURF4 promotes the efficient cellular secretion of PCSK9. eLife 2018, 7
    6. Delia Susan-Resiga, Emmanuelle Girard, Robert Scott Kiss, Rachid Essalmani, Josée Hamelin, Marie-Claude Asselin, Zuhier Awan, Chutikarn Butkinaree, Alexandre Fleury, Armand Soldera, Yves L. Dory, Alexis Baass, Nabil G. Seidah. The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation. Journal of Biological Chemistry 2017, 292 (5) , 1573-1590.
    7. Kévin Ly, Rachid Essalmani, Roxane Desjardins, Nabil G. Seidah, Robert Day. An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells. Journal of Biological Chemistry 2016, 291 (47) , 24676-24687.
    8. Rahul C Deo, Gabriel Musso, Murat Tasan, Paul Tang, Annie Poon, Christiana Yuan, Janine F Felix, Ramachandran S Vasan, Rameen Beroukhim, Teresa De Marco, Pui-Yan Kwok, Calum A MacRae, Frederick P Roth. Prioritizing causal disease genes using unbiased genomic features. Genome Biology 2014, 15 (12)
    9. Nabil G. Seidah, Zuhier Awan, Michel Chrétien, Majambu Mbikay. PCSK9. Circulation Research 2014, 114 (6) , 1022-1036.
    10. Mariana Pehar, Luigi Puglielli. Lysine acetylation in the lumen of the ER: A novel and essential function under the control of the UPR. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2013, 1833 (3) , 686-697.
    11. Michel Chrétien. My road to Damascus: how I converted to the prohormone theory and the proprotein convertases. Biochemistry and Cell Biology 2012, 90 (6) , 750-768.
    12. Nicola Ferri. Proprotein Convertase Subtilisin/Kexin Type 9: From the Discovery to the Development of New Therapies for Cardiovascular Diseases. Scientifica 2012, 2012 , 1-21.
    13. Budhaditya Mazumdar, Arup Banerjee, Keith Meyer, Ranjit Ray. Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes. Hepatology 2011, 54 (4) , 1149-1156.